News
Latest news and updates on the project.
November 2024
Ms. Boukle Ellen has joined as the project manager for Immunosarbor
Ms. Boukle Ellen (email: boukje.ehlen@maastrichtuniversity.nl ) has joined as the project manager for Immunosarbor. She brings extensive experience with European grants, which will be invaluable to the project’s success.
A new student assistant, Feline Geels, has joined our team
A new student assistant, Feline Geels, has joined our team. Her role involves assisting with remote data monitoring, which is crucial for ensuring data cleaning and completeness before data analysis
On-site monitoring for the ImmunoSABR project has officially started
On-site monitoring for the ImmunoSABR project has officially started. Following the completion of remote monitoring at all 11 centers, on-site monitoring visits have been scheduled for 8/11 of the centers between November 24 and December 24. These visits are a key step in ensuring the quality and accuracy of data collection across the project. Sillar (https://sillar-clinical.com/) and CTCM (https://www.ctcm.nl/ ) will be conducting the on-site monitoring visits for the ImmunoSABR project. CTCM will handle the visits for Dutch-speaking sites, while Sillar will oversee the visits at non-Dutch-speaking centers.
List of (planned) completion of monitoring per site:
Site 001_MUMC+ 06-jan-2024
Site 002-NKI 21-Nov-2024
Site 004 KUL 9-Dec-2024
Site 005 SLB 14-Nov-2024
Site 006 UZG 27-Nov-2024
Site 009 COL 21-Nov-2024
Site 014 HUH 3-Dec-2024
We are currently in discussions with the company Ingedata to segment lesions in imaging data from patients in the Immunosarbor trial
We are currently in discussions with the company Ingedata to segment lesions in imaging data from patients in the Immunosarbor trial. This will give us information on how drug ImmunoSABR affects lesions in time. In this project, we are collaborating with “Data Hub” and MEMIC, who will manage the secure transfer of data. In this project AI Redbrick annotation platform will be used. https://redbrickai.com/ The platform’s AI capabilities will support the project in identifying key patterns and insights from the data.
We have established a contract with company “BaseClear” for microbiome analysis of the collected samples (both control arm and experimental arm).
We have established a contract with company “BaseClear” for microbiome analysis of the collected samples (both control arm and experimental arm). Our goal is to externally validate and publish microbiome signatures that serve as prognostic factors for patients undergoing immunotherapy. https://pubmed.ncbi.nlm.nih.gov/29097494/
We recently signed an agreement with the company “Qualiblood” to analyze blood samples from patients enrolled in immunosabr
We recently signed an agreement with the company “Qualiblood” to analyze blood samples from patients enrolled in immunosabr. This analysis will test new circulating hypoxia biomarkers, not only in patients but also in mice with varying tumoral hypoxia levels.
October 2024
collaboration with a bioinformatician from Maastricht University Medical Centre (MUMC+)
We are collaboration with a bioinformatician from Maastricht University Medical Centre (MUMC+), who will conduct data analysis for ImmunoSABR focused on identifying both responders and non-responders of patients enrolled in the study.
June 2024
We have established an agreement with KU Leuven to analyze immunological serum biomarkers in blood samples from patients enrolled in ImmunoSABR
We have established an agreement with KU Leuven to analyze immunological serum biomarkers in blood samples from patients enrolled in ImmunoSABR. The analysis will utilize a targeted approach with the sFIS assay, enabling detailed insights into immune responses and advancing the project’s research objectives. https://pubmed.ncbi.nlm.nih.gov/34795003/
May 2024
All biomaterials have been successfully transferred from the 11 participating centers to the Maastricht Central Biobank
All biomaterials have been successfully transferred from the 11 participating centers to the Maastricht Central Biobank. This marks a significant milestone in the project, ensuring that all collected samples are now securely stored for future research and analysis
January 2024
Recruitment for the randomized phase 2 trial immunosabr has concluded, with a total of 88 patients included (44 in control arm and 44 in experimental arm).
Recruitment for the randomized phase 2 trial immunosabr has concluded, with a total of 88 patients included (44 in control arm and 44 in experimental arm).
November 2023
An interpretable model of radiomics analysis developped during immunosabr has been applied to elastography of the liver
An interpretable model of radiomics analysis developped during immunosabr has been applied to elastography of the liver: https://pubmed.ncbi.nlm.nih.gov/37958476/
March 2023
A model to calculate uncertainty of radiomics analysis developped during immunosabr has been applied to head and neck cancer
A model to calculate uncertainty of radiomics analysis developped during immunosabr has been applied to head and neck cancer https://pubmed.ncbi.nlm.nih.gov/37046593/
March 2023 – Newsletter
March 2023 Newsletter : More info
December 2022
December 2022 – Newsletter
December 2022 Newsletter: More info
September 2022
September 2022 – Newsletter
Sep 2022 Newsletter: More info
June 2022
June 2022 – Newsletter
June 2022 Newsletter : More info
August 2020
Eight Patients are now Enrolled in the ImmuoSABR Clinical Trial
Our trial is steadily progressing and we now have eight patients in three centres enrolled in the ImmunoSABR trial .
February 2020
First Patients Enrolled in ImmuoSABR Clinical Trial
Great news the first patients have been enrolled in the ImmunoSABRclinical Trial at NKI and AZM
June 2019
METC Approval
METC approval received for the centres in Maastricht, Amsterdam and Nijmegen
February 2019
Annual ImmunoSABR Meeting 2019
Partners Meeting held in Amsterdam reporting on the progress of the project.
December 2018
New ImmunoSABR Website Launched
A new website has been designed to provide an overview of the ImmunoSABR project, its progress and information to the general public, patients and potential patients
October 2018
Presentation – Brussels & Roma
Professor Philippe Lambin – Immunocytokines and Radiation at the Institut Bordet, Brussels. Unconventional immunotherapy and Radiation given in Roma at the yearly national course of radiation Oncology
September 2018
Presentation – Paris
Professor Philippe Lambin given in Paris at the Immunorad meeting immunocytokines and radiation
August 2018
Presentation – New York
Professor Philippe Lambin given in New York MSKCC on Immunocytokines and radiation
July 2018
Presentation – Liverpool UK
Professor Philippe Lambin on Immunocytokines and Radiation given in Liverpool UK at UK Radiological Congress and Radiation and Oncology Congress (UKRCO)
STAY INFORMED ?
If you want to stay informed about ImmunoSABR project, please subscribe to our newsletter.
CONTACT
The D-Lab / Precision Medicine
P.O. Box 616,
6200 MD Maastricht, The Netherlands
FUNDING
This project has received funding from the European Union’s. Horizon 2020 research and innovation programme under grant agreement No 733008
